Saudi Arabia Over-The-Counter Pharmaceutical Market Size, Share, Growth & Demand Report 2026-2034

IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Saudi Arabia over-the-counter pharmaceutical market. The Saudi Arabia over-the-counter pharmaceutical market increased from USD 1.74 Billion in 2025 to USD 1.83 Billion in 2026, and is projected to reach USD 2.74 Billion by 2034, exhibiting a CAGR of 5.20% during 2026-2034, driven by rising self-medication trends, expanding retail pharmacy and online distribution networks, and growing prevalence of minor ailments and lifestyle diseases.

OTC pharmaceuticals benefit from the everyday nature of consumer health demand in Saudi Arabia, with common colds, allergies, pain, and digestive complaints driving repeat purchases of accessible remedies across the Kingdom. The market is forecast to add USD 0.91 Billion in incremental value between 2026 and 2034, with three structural forces shaping this trajectory: rising self-medication trends and health awareness growth, expanding retail pharmacy and online distribution networks, and growing prevalence of minor ailments and lifestyle diseases.

Saudi Arabia Over-The-Counter Pharmaceutical Market at a Glance:

• Market Size (2025): USD 1.74 Billion
• Market Size (2026): USD 1.83 Billion
• Forecast Market Size (2034): USD 2.74 Billion
• CAGR (2026-2034): 5.20%
• Leading Distribution Channel (2025): Pharmacies and Drug Stores, 68.4% share
• Leading Formulation (2025): Tablets and Capsules, 49.6% share
• Leading Region (2025): Northern and Central Region, 41.5% share
• Fastest-Growing Distribution Channel: Online Retail, approximately 8.6% CAGR

How AI is Reshaping the Future of the Saudi Arabia Over-The-Counter Pharmaceutical Market

• Digital Health App-Based Product Discovery: Rising digital health app adoption is accelerating app-based OTC product discovery, comparison, and purchase, while symptom-checker and AI-guided recommendation features are enhancing personalized product selection for consumers across the Kingdom.
• Digitally Connected Pharmacy Ecosystems: Platforms such as PharmaConnect, launched by Haleon and Apex Loyalty in August 2025 to engage more than 15,000 pharmacies through digital ordering and behavior-based loyalty, are modernizing how OTC products reach consumers as e-commerce adoption accelerates.
• Advanced Formulation and Delivery Technologies: Manufacturers are advancing tablet, capsule, liquid, and topical technologies, including transdermal patch and gel-based systems and standardized plant extracts, to improve bioavailability, sustained-release performance, and consumer trust in efficacy.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-over-the-counter-pharmaceutical-market/requestsample

Saudi Arabia Over-The-Counter Pharmaceutical Market Trends and Drivers:

Rising self-medication trends and health awareness growth are the foundational drivers behind the market's expansion, as Saudi Arabia strengthens consumer health literacy through preventive-care education, Arabic-language resources, and initiatives such as Haleon's Pain Management Institute. Pharmacies and Drug Stores lead the distribution channel mix at 68.4% share in 2025, reflecting sustained consumer preference for pharmacist-guided purchases, while Tablets and Capsules, at 49.6% share, remain the primary self-medication delivery format across the Kingdom.

Rising prevalence of minor ailments and a supportive regulatory framework are reshaping the product portfolio on top of these demand drivers. Studies indicate that allergy prevalence among Saudi children ranges from 13% to 45%, increasing demand for accessible remedies, while the Northern and Central Region's dominant 41.5% share in 2025 reflects its concentration of population, retail pharmacy density, and healthcare infrastructure. The Southern Region, though smallest at 11.2% share, represents an emerging opportunity as retail pharmacy infrastructure and regional distribution networks expand. Favorable SFDA policy enabling prescription-to-OTC switches is simultaneously broadening the addressable OTC product portfolio.

Regulatory Support and Healthcare Initiatives Driving Demand:

• SFDA Rx-to-OTC Switch Policy: Favorable regulatory policy enabling prescription-to-OTC product switches is broadening the addressable OTC product portfolio, with increasing SFDA alignment with international switch precedents accelerating approval timelines for globally established molecules.
• Consumer Health Literacy Programs: Preventive-care education, Arabic-language resources, culturally tailored programs, and initiatives such as Haleon's Pain Management Institute are strengthening consumer health literacy and the preference for self-managed treatment of minor ailments.
• Drug Track and Trace Enforcement: The Saudi Food and Drug Authority fined 10 pharmacies more than SR1.7 million for violations of the electronic Drug Track and Trace System, reinforcing supply chain compliance and consumer trust in registered OTC products.
• Domestic Pharmaceutical Manufacturing Investment: In January 2026, Saudi Arabia launched major Jeddah investments, including a SAR 650 million pharmaceutical factory with an annual capacity of 450 million units, strengthening local production capacity and supply resilience.
• Local Manufacturing Capacity Expansion: In April 2026, Jamjoom Pharma signed an agreement to acquire Pfizer's oral solid-dose manufacturing facility in King Abdullah Economic City, subject to regulatory approvals, strengthening domestic production and healthcare access across the Middle East and Africa.

Saudi Arabia Over-The-Counter Pharmaceutical Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Product Type:

• Analgesics
• Cold and Cough Remedies
• Vitamins and Dietary Supplements
• Gastrointestinal Products
• Dermatological
• Others

Breakup By Distribution Channel:

• Pharmacies and Drug Stores
• Supermarkets and Hypermarkets
• Online Retail
• Others

Pharmacies and Drug Stores command a 68.4% majority share in 2025, reflecting sustained consumer trust in pharmacist-guided OTC product recommendations. Supermarkets and Hypermarkets hold 16.5%, while Online Retail at 10.1% is the fastest-growing channel at approximately 8.6% CAGR as e-commerce and digital health platform adoption accelerates, and other channels account for 5.0%.

Breakup By Formulation:

• Tablets and Capsules
• Liquids and Syrups
• Topicals (Creams, Ointments)
• Others

Tablets and Capsules dominate at 49.6% share in 2025, supported by their established role as the primary self-medication delivery format across the Kingdom. Liquids and Syrups hold 24.3%, supporting pediatric and elderly-friendly product needs, while Topicals, at 18.4% share, serve pain relief, dermatological, and preventive care applications.

Breakup By Region:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

The Northern and Central Region commands 41.5% share in 2025, anchored by its concentration of population, retail pharmacy density, and healthcare infrastructure. The Western Region follows at 27.4%, sustained by strong pharmacy chain presence and expanding pilgrimage-driven consumer demand, while the Eastern Region holds 19.9% on growing industrial workforce demand and retail infrastructure investment, and the Southern Region's 11.2% share reflects emerging retail pharmacy infrastructure development and regional distribution expansion.

Competitive Landscape:

The Saudi Arabia over-the-counter pharmaceutical market exhibits moderate concentration, with domestic manufacturers competing alongside regional and global pharmaceutical majors. The report provides detailed profiles of all major companies, including:

• Jamjoom Pharma
• Astra Industrial Group (Tabuk Pharmaceuticals)
• SPIMACO
• Hikma Pharmaceuticals PLC
• Pfizer Inc.

Jamjoom Pharma and Astra Industrial Group lead the market through comprehensive domestic manufacturing infrastructure and extensive retail distribution capacity, supported by continuous investment. SPIMACO, Hikma Pharmaceuticals PLC, and Pfizer Inc. compete through production scale, multinational brand strength, and consumer health differentiation, respectively.

Market Concentration Analysis:

• Concentration: The market exhibits moderate concentration, with Jamjoom Pharma, Astra Industrial Group, and SPIMACO collectively accounting for a significant share of total category revenue in 2025
• Segment Leadership: Jamjoom Pharma and Astra Industrial Group lead through domestic manufacturing and distribution portfolios, while SPIMACO and Hikma Pharmaceuticals PLC compete on production scale and Pfizer Inc. on multinational brand differentiation
• Consolidation Trend: Consolidation pressure remains limited as leading manufacturers maintain distinct strategic positioning rather than pursuing direct M&A, though capacity-led moves such as Jamjoom Pharma's facility acquisition are strengthening local manufacturing

What Does The Full Report Cover?

If you are tracking the Saudi Arabia over-the-counter pharmaceutical market for investment decisions, market entry planning, competitive benchmarking, or strategic advisory, IMARC Group's report gives you everything in one place:

• Complete market sizing in value terms with forecasts covering the full 2026-2034 projection period
• Quantified analysis of market drivers, restraints, opportunities, and challenges across product type, distribution channel, formulation, and regional markets
• Sub-segment breakdowns across product types, four distribution channels, formulations, and four regions, each with individual share and CAGR data
• Competitive profiles of Jamjoom Pharma, Astra Industrial Group, SPIMACO, Hikma Pharmaceuticals PLC, and Pfizer Inc. with strategic positioning analysis
• Value chain analysis, market concentration assessment, Porter's five forces analysis, and technology landscape coverage across formulation and delivery innovation
• Latest trends covering online pharmacy and e-commerce growth, SFDA Rx-to-OTC switch expansion, digital health app-based product discovery, and natural and herbal OTC product innovation shaping market competition across the Kingdom

Recent News and Developments in Saudi Arabia Over-The-Counter Pharmaceutical Market

• April 2026: Jamjoom Pharma signed an agreement to acquire Pfizer's pharmaceutical manufacturing facility in King Abdullah Economic City, subject to regulatory approvals, strengthening local manufacturing capacity, supply resilience, and healthcare access across the Middle East and Africa.
• January 2026: Saudi Arabia launched major Jeddah investments, including a SAR 650 million pharmaceutical factory with an annual capacity of 450 million units for intravenous solutions, eye drops, and cardiac and emergency medications.
• September 2025: Tabuk Pharmaceuticals and Hanmi Pharmaceutical signed an exclusive licensing and supply agreement for Rolontis (eflapegrastim) across Saudi Arabia and the wider MENA region.
• August 2025: Haleon and Apex Loyalty launched PharmaConnect in Saudi Arabia, a digital ordering and behavior-based loyalty platform designed to engage more than 15,000 pharmacies.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

Key Questions This Report Answers

• What is the current Saudi Arabia over-the-counter pharmaceutical market size and what is its projected value?
• Which distribution channel and formulation hold the largest share in the Saudi Arabia over-the-counter pharmaceutical market?
• What are the key drivers of Saudi Arabia over-the-counter pharmaceutical market growth?
• Which region dominates the Saudi Arabia over-the-counter pharmaceutical market and which distribution channel is growing fastest?
• How are self-medication trends, SFDA Rx-to-OTC switch policy, and online distribution reshaping the Saudi Arabia over-the-counter pharmaceutical industry?
• Who are the top companies in the Saudi Arabia over-the-counter pharmaceutical market and what are their competitive strategies?
• What are the investment and market entry opportunities across digital health integration, natural and herbal products, and e-commerce distribution in Saudi Arabia?

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104